Werewolf Therapeutics Inc. Announces Participation in Investor Conferences

Werewolf Therapeutics, Inc., a biotechnology company specializing in oncology biotherapeutics, has announced its participation in upcoming investor conferences. Based in Cambridge, United States, the company operates within the health care sector, focusing on the development of novel immuno-stimulatory therapeutics and medications aimed at treating cancer diseases.

As of the latest available data, Werewolf Therapeutics’ stock price closed at $0.949 USD. The company’s stock has experienced significant volatility, with a 52-week high of $5.84 USD on May 7, 2024, and a 52-week low of $0.595 USD on April 6, 2025. This fluctuation underscores the inherent volatility within the biotech sector.

Werewolf Therapeutics, Inc. is listed on the Nasdaq exchange and has a market capitalization of $39,080,458 USD. The company’s recent participation in investor conferences is a strategic move to engage with investors and stakeholders, providing updates on its ongoing projects and future plans in the field of cancer treatment.

The company’s focus on developing innovative therapies positions it as a key player in the oncology sector, aiming to address the critical need for effective cancer treatments. As Werewolf Therapeutics continues to advance its research and development efforts, its participation in investor conferences serves as an opportunity to highlight its progress and potential in the competitive biotech landscape.